Navigation Links
Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference

TARRYTOWN, N.Y., Oct. 27 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 18th Annual Credit Suisse Healthcare Conference on Wednesday, November 11, 2009. The presentation is scheduled for 1:30 p.m. Eastern Time. The session may be accessed through the Company's web site,, on the Investor Relations page under the Presentations heading. An archived version of the presentation will be available after the live webcast through December 13, 2009. Additional information about Regeneron and recent news releases are available on the Regeneron web site.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders.

    Contacts Information:

    Peter Dworkin                             Laura Lindsay
    Investor Relations                        Media Relations
    914.345.7640                              914.345.7800     

SOURCE Regeneron Pharmaceuticals, Inc.

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Inverness Medical Innovations Announces Third Quarter 2009 Results
5. Logical Therapeutics Announces Positive Results of LT-NS001 vs. Naproxen Clinical Study
6. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
7. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
8. Genomma Lab Internacional Announces Third Quarter 2009 Results
9. ATS Medical Announces Third Quarter 2009 Earnings Release Date and Conference Call
10. Trubion Announces Upcoming Presentation at 8th Annual BIO Investor Forum
11. Sequenom Announces Paul Maier to Become Interim Chief Financial Officer
Post Your Comments:
(Date:11/26/2015)... 2015 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ... demands kidney transplantation is expected to boost the market growth, ... organ transplantation. --> 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Japanese ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they ... to buy during the Black Friday and Cyber Monday massage chair sales ... the Internet high and low to find the best massage chair deals, they can ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... real-time eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean ... Nuclear Medicine tests directly from their electronic medical record (EMR) without the need ...
(Date:11/26/2015)... ... November 26, 2015 , ... Somu ... As a franchise owner, Somu now offers travelers, value and care based Travel ... private cruise sales, as well as, cabin upgrades and special amenities such as, ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical ... professionals and offered by healthcare staffing agency Aureus Medical Group . ... of October 2015 among those searching for healthcare jobs through the company’s website, ...
Breaking Medicine News(10 mins):